ABIOMED (NASDAQ:ABMD) PT Raised to $259.00

ABIOMED (NASDAQ:ABMD) had its price objective boosted by Morgan Stanley from $204.00 to $259.00 in a research note published on Friday, February 2nd. They currently have an equal weight rating on the medical equipment provider’s stock.

Several other research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of ABIOMED from a hold rating to a sell rating in a research note on Tuesday, October 10th. BTIG Research downgraded shares of ABIOMED from a buy rating to a neutral rating in a research note on Monday, October 16th. Piper Jaffray Companies increased their price objective on shares of ABIOMED to $200.00 and gave the company an overweight rating in a research note on Thursday, October 26th. Jefferies Group raised their price target on shares of ABIOMED from $208.00 to $220.00 and gave the stock a buy rating in a research report on Thursday, December 21st. Finally, Leerink Swann restated an outperform rating and issued a $200.00 price target (up from $180.00) on shares of ABIOMED in a research report on Thursday, October 12th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $263.86.

ABIOMED (ABMD) opened at $233.72 on Friday. ABIOMED has a 52-week low of $107.33 and a 52-week high of $255.42. The company has a market cap of $10,156.45, a P/E ratio of 118.04, a P/E/G ratio of 3.04 and a beta of 0.36.

ABIOMED (NASDAQ:ABMD) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.20. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The company had revenue of $154.00 million during the quarter, compared to analyst estimates of $154.00 million. During the same quarter in the prior year, the business earned $0.34 earnings per share. The business’s quarterly revenue was up 34.9% compared to the same quarter last year. research analysts predict that ABIOMED will post 2.39 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in ABMD. Koch Industries Inc. boosted its holdings in shares of ABIOMED by 40,431.3% in the second quarter. Koch Industries Inc. now owns 799,277 shares of the medical equipment provider’s stock worth $794,000 after buying an additional 797,305 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of ABIOMED by 102.0% during the third quarter. Janus Henderson Group PLC now owns 1,076,829 shares of the medical equipment provider’s stock worth $181,553,000 after purchasing an additional 543,793 shares during the period. American Century Companies Inc. boosted its holdings in shares of ABIOMED by 99.0% during the fourth quarter. American Century Companies Inc. now owns 963,517 shares of the medical equipment provider’s stock worth $180,573,000 after purchasing an additional 479,375 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of ABIOMED by 2,219.4% during the third quarter. Wells Fargo & Company MN now owns 364,427 shares of the medical equipment provider’s stock worth $61,443,000 after purchasing an additional 348,715 shares during the period. Finally, FMR LLC acquired a new stake in shares of ABIOMED during the second quarter worth approximately $32,609,000. Institutional investors own 90.35% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/13/abiomed-abmd-pt-raised-to-259-00.html.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply